irofulven has been researched along with Adenocarcinoma Of Kidney in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Börcsök, J; Csabai, I; Diossy, M; Duan, H; Hanlon, T; Klus, GT; Mouw, KW; Offit, K; Pappot, H; Pathania, S; Prosz, A; Ried, T; Sahgal, P; Sethi, N; Spisak, S; Stormoen, DR; Szallasi, Z; Sztupinszki, Z; Tisza, V; Topka, S; Vijai, J; Vizkeleti, L | 1 |
| Amato, RJ; Pagliaro, L; Perez, C | 1 |
| Berg, WJ; Mazumdar, M; Motzer, RJ; Schwartz, L; Yu, R | 1 |
2 trial(s) available for irofulven and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Sesquiterpenes | 2002 |
Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Sesquiterpenes; Treatment Outcome | 2001 |
1 other study(ies) available for irofulven and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.
Topics: Carcinoma, Renal Cell; DNA Damage; DNA Repair; Humans; Kidney Neoplasms; Sesquiterpenes; Ultraviolet Rays; Xeroderma Pigmentosum Group D Protein | 2023 |